Pancreatic Cancer Research

ResearcherKanagawa Cancer CenterActive in the last 2 years

Shun Tezuka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2642-1658; OpenAlex author ID A5058421674. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: 3 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 11

  1. Peritoneum carcinomatosis as a favourable prognostic factor for treatment with nanoliposomal irinotecan and fluorouracil plus leucovorin in advanced pancreatic… Co-author DOI 10.1177/17588359251351540↗
  2. Early tumor shrinkage as a prognostic predictor in chemotherapy-naïve patients with locally advanced pancreatic cancer treated with modified FOLFIRINOX or gemc… Co-author DOI 10.1016/j.pan.2024.07.006↗
  3. FOLFOX regimen after failure of fluorouracil and leucovorin plus nanoliposomal-irinotecan therapy for advanced pancreatic cancer: a retrospective observational… First author DOI 10.1186/s12885-023-10654-3↗
  4. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysi… Co-author DOI 10.1002/cam4.4512↗
  5. Nal-IRI/5-FU/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: A single center retrospective study. Co-author DOI 10.1016/j.pan.2022.06.004↗
  6. Prognostic significance of sarcopenia as determined by bioelectrical impedance analysis in patients with advanced pancreatic cancer receiving gemcitabine plus … Co-author DOI 10.3892/ol.2022.13495↗
  7. Tissue factor and its procoagulant activity on cancer-associated thromboembolism in pancreatic cancer. Co-author DOI 10.1111/cas.15106↗
  8. A Multicenter Retrospective Study of Gemcitabine Plus Nab-Paclitaxel for Elderly Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001484↗
  9. Predictive value of ERCC1, ERCC2, ERCC4, and glutathione S-Transferase Pi expression for the efficacy and safety of FOLFIRINOX in patients with unresectable pa… Co-author PMID 30416859↗
  10. Duodenal stenting followed by systemic chemotherapy for patients with pancreatic cancer and gastric outlet obstruction. Co-author DOI 10.1016/j.pan.2016.07.007↗
  11. Unexpected Side Effects of a High S-1 Dose: Subanalysis of a Phase III Trial Comparing Gemcitabine, S-1 and Combinatorial Treatments for Advanced Pancreatic Ca… Co-author DOI 10.1159/000446989↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Makoto Ueno · 11 shared papers, 2016–2025 · strength 1.36
  2. Satoshi Kobayashi · 10 shared papers, 2016–2025 · strength 1.28
  3. Manabu Morimoto · 9 shared papers, 2016–2023 · strength 0.97
  4. Shin Maeda · 5 shared papers, 2018–2025 · strength 0.73
  5. Yuichiro Tozuka · 5 shared papers, 2018–2025 · strength 0.68
  6. Shuhei Nagashima · 4 shared papers, 2021–2023 · strength 0.57
  7. Junji Furuse · 3 shared papers, 2023–2025 · strength 0.56
  8. Shinichi Ohkawa · 4 shared papers, 2016–2022 · strength 0.32
  9. Hiroyuki Asama · 2 shared papers, 2022 · strength 0.27
  10. Masafumi Ikeda · 2 shared papers, 2020–2024 · strength 0.25
  11. Masato Ozaka · 2 shared papers, 2020–2024 · strength 0.25
  12. Hiroshi Imaoka · 2 shared papers, 2020–2024 · strength 0.25
  13. Masaaki Murakawa · 1 shared paper, 2025 · strength 0.22
  14. Naoto Yamamoto · 1 shared paper, 2025 · strength 0.22
  15. Yohei Miyagi · 2 shared papers, 2018–2021 · strength 0.19
  16. Soichiro Morinaga · 2 shared papers, 2016–2022 · strength 0.19
  17. Naoya Kato · 1 shared paper, 2024 · strength 0.17
  18. Takeshi Terashima · 1 shared paper, 2024 · strength 0.17
  19. Keiji Sano · 1 shared paper, 2024 · strength 0.17
  20. Kohei Nakachi · 1 shared paper, 2024 · strength 0.17
  21. Michiaki Unno · 1 shared paper, 2024 · strength 0.17
  22. Chigusa Morizane · 1 shared paper, 2024 · strength 0.17
  23. Maeda Shin · 1 shared paper, 2022 · strength 0.15
  24. Shiro Koizume · 1 shared paper, 2021 · strength 0.11
  25. Ikuhiro YAMADA · 1 shared paper, 2020 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.